These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta®) and its effect on total sleep time, headache frequency, and daytime functioning: A randomized, double-blind, placebo-controlled, parallel-group, pilot study. Spierings EL; McAllister PJ; Bilchik TR Cranio; 2015 Apr; 33(2):115-21. PubMed ID: 25323219 [TBL] [Abstract][Full Text] [Related]
23. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Rosenberg R; Caron J; Roth T; Amato D Sleep Med; 2005 Jan; 6(1):15-22. PubMed ID: 15680290 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of indiplon in older adults with primary insomnia. Walsh JK; Moscovitch A; Burke J; Farber R; Roth T Sleep Med; 2007 Nov; 8(7-8):753-9. PubMed ID: 17825616 [TBL] [Abstract][Full Text] [Related]
25. The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. Tek C; Palmese LB; Krystal AD; Srihari VH; DeGeorge PC; Reutenauer EL; Guloksuz S Schizophr Res; 2014 Dec; 160(1-3):180-5. PubMed ID: 25454802 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Lankford A; Rogowski R; Essink B; Ludington E; Heith Durrence H; Roth T Sleep Med; 2012 Feb; 13(2):133-8. PubMed ID: 22197474 [TBL] [Abstract][Full Text] [Related]
27. The role of eszopiclone in the treatment of insomnia. Morin AK; Willett K Adv Ther; 2009 May; 26(5):500-18. PubMed ID: 19513631 [TBL] [Abstract][Full Text] [Related]
28. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Walsh JK; Krystal AD; Amato DA; Rubens R; Caron J; Wessel TC; Schaefer K; Roach J; Wallenstein G; Roth T Sleep; 2007 Aug; 30(8):959-68. PubMed ID: 17702264 [TBL] [Abstract][Full Text] [Related]
29. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Joffe H; Petrillo L; Viguera A; Koukopoulos A; Silver-Heilman K; Farrell A; Yu G; Silver M; Cohen LS Am J Obstet Gynecol; 2010 Feb; 202(2):171.e1-171.e11. PubMed ID: 20035910 [TBL] [Abstract][Full Text] [Related]
30. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Sangal RB; Blumer JL; Lankford DA; Grinnell TA; Huang H Pediatrics; 2014 Oct; 134(4):e1095-103. PubMed ID: 25266438 [TBL] [Abstract][Full Text] [Related]
31. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Krystal AD; Walsh JK; Laska E; Caron J; Amato DA; Wessel TC; Roth T Sleep; 2003 Nov; 26(7):793-9. PubMed ID: 14655910 [TBL] [Abstract][Full Text] [Related]
32. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Zammit GK; McNabb LJ; Caron J; Amato DA; Roth T Curr Med Res Opin; 2004 Dec; 20(12):1979-91. PubMed ID: 15701215 [TBL] [Abstract][Full Text] [Related]
34. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Walsh JK; Thacker S; Knowles LJ; Tasker T; Hunneyball IM Sleep Med; 2009 Sep; 10(8):859-64. PubMed ID: 19345644 [TBL] [Abstract][Full Text] [Related]
35. Validation of the sleep impact scale in patients with major depressive disorder and insomnia. Lasch K; Joish VN; Zhu Y; Rosa K; Qiu C; Crawford B Curr Med Res Opin; 2009 Jul; 25(7):1699-710. PubMed ID: 19505198 [TBL] [Abstract][Full Text] [Related]
36. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Menza M; Dobkin RD; Marin H; Gara M; Bienfait K; Dicke A; Comella CL; Cantor C; Hyer L Mov Disord; 2010 Aug; 25(11):1708-14. PubMed ID: 20589875 [TBL] [Abstract][Full Text] [Related]
37. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Scharf M; Erman M; Rosenberg R; Seiden D; McCall WV; Amato D; Wessel TC Sleep; 2005 Jun; 28(6):720-7. PubMed ID: 16477959 [TBL] [Abstract][Full Text] [Related]
38. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Roth T; Seiden D; Sainati S; Wang-Weigand S; Zhang J; Zee P Sleep Med; 2006 Jun; 7(4):312-8. PubMed ID: 16709464 [TBL] [Abstract][Full Text] [Related]
39. Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. Liang L; Huang Y; Xu R; Wei Y; Xiao L; Wang G Sleep Med; 2019 Oct; 62():6-13. PubMed ID: 31518944 [TBL] [Abstract][Full Text] [Related]